Zacks Research Has Bullish Forecast for Amarin Q2 Earnings

Amarin Corporation PLC (NASDAQ:AMRN) – Stock analysts at Zacks Research increased their Q2 2026 earnings estimates for Amarin in a research report issued to clients and investors on Wednesday, June 17th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of ($0.21) for the quarter, up from their previous estimate of ($0.22). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Amarin’s current full-year earnings is ($1.15) per share. Zacks Research also issued estimates for Amarin’s Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.14) EPS, FY2027 earnings at ($0.89) EPS, Q1 2028 earnings at ($0.17) EPS and FY2028 earnings at ($0.69) EPS.

A number of other research firms also recently weighed in on AMRN. Wall Street Zen downgraded Amarin from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amarin in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $12.00.

Amarin Stock Performance

Shares of NASDAQ:AMRN opened at $16.03 on Friday. Amarin has a 52 week low of $12.30 and a 52 week high of $20.90. The firm has a market cap of $336.15 million, a PE ratio of -24.66 and a beta of 0.82. The firm’s fifty day moving average is $14.62 and its 200-day moving average is $14.74.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AMRN. Jones Financial Companies Lllp lifted its position in shares of Amarin by 449,522.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company’s stock worth $815,000 after purchasing an additional 1,811,574 shares during the period. Millennium Management LLC boosted its stake in shares of Amarin by 192.6% in the 3rd quarter. Millennium Management LLC now owns 132,391 shares of the biopharmaceutical company’s stock valued at $2,169,000 after purchasing an additional 87,147 shares during the last quarter. Waterfront Wealth Inc. boosted its stake in shares of Amarin by 82.8% in the 4th quarter. Waterfront Wealth Inc. now owns 142,540 shares of the biopharmaceutical company’s stock valued at $1,990,000 after purchasing an additional 64,580 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Amarin during the second quarter worth $623,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Amarin during the first quarter worth $278,000. Institutional investors own 22.25% of the company’s stock.

Amarin News Roundup

Here are the key news stories impacting Amarin this week:

• Positive Sentiment: Zacks Research upgraded Amarin to Strong-Buy, which is a supportive signal for sentiment and may be contributing to the stock’s recent strength. Zacks.com
• Positive Sentiment: Analysts raised earnings estimates for several periods, including FY2026, FY2027, and some quarterly forecasts, suggesting a slightly better outlook for Amarin’s loss trajectory over time. MarketBeat AMRN
• Neutral Sentiment: Not all revisions were positive: Zacks also trimmed some near-term estimates, including Q3 2026, Q4 2026, and Q1 2028 EPS, which tempers the bullish message. MarketBeat AMRN
• Negative Sentiment: The company is still expected to post losses across the forecast period, with consensus full-year earnings remaining negative, so fundamentals are not yet showing a profit turnaround. MarketBeat AMRN

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.